Core Points - Aecon Group Inc. announced the election of its board of directors, with nominees holding office until the next Annual General Meeting [1] - Monica Sloan retired from the board after 12 years of service, contributing to various committees [2][3] - Shareholders approved all resolutions, including executive compensation and the re-appointment of PricewaterhouseCoopers LLP as auditors [4] Election of Directors - John M. Beck received 92.29% votes in favor, while Susan Wolburgh received 95.78% [5] - Leslie Kass, Stuart Lee, and Rod Phillips received over 96% votes in favor [5] - Scott Stewart had the highest approval at 99.40% [5] Advisory Vote on Executive Compensation - The advisory vote on executive compensation received 94.66% votes in favor [6] Appointment and Remuneration of Auditors - The appointment of auditors received 96.60% votes in favor, with 3.40% votes withheld [7] Dividend Announcement - Aecon's board approved a quarterly dividend of 19 cents per common share, payable on July 3, 2025 [8] Company Overview - Aecon Group Inc. is a North American construction and infrastructure development company, providing integrated solutions across various sectors [9]

Targets 41% Revenue Growth, 30% Profit Growth, and a Q3 2025 IPO of Its Capital Markets SubsidiaryKUALA LUMPUR, Malaysia, June 03, 2025 (GLOBE NEWSWIRE) -- VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), a diversified global holding company with a strategic focus on AI & Robotics, Fintech, Cybersecurity, Renewable Energy, and Capital Market Consultancy, today announced its financial guidance for the fiscal year ending December 31, 2025. For 2025, the Company projects approximately 41% yea ...

Company Overview - Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for serious rare and ultra-rare genetic diseases [3] - The company has established a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical needs [3] Management and Strategy - The management team of Ultragenyx is experienced in the development and commercialization of therapeutics for rare diseases [4] - The company's strategy emphasizes time- and cost-efficient drug development to deliver safe and effective therapies to patients urgently [4] Upcoming Events - Emil Kakkis, M.D., Ph.D., the CEO of Ultragenyx, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, at 10:00 a.m. ET [1] - A live and archived webcast of the panel will be available on the company's website [2]

Core Points - Sprott Focus Trust, Inc. has declared a quarterly distribution of $0.1280 per share, payable on June 30, 2025, to stockholders of record as of June 13, 2025 [1] - The Fund has a Distribution Policy of paying quarterly distributions at an annual rate of 6% based on the rolling average of the prior four calendar quarter-end net asset values (NAVs) [2] - The estimated sources of the upcoming distribution include net investment income, short-term gains, and long-term gains, with specific allocations detailed [3] Distribution and Performance Information - The Fund's average annual total return in relation to NAV for the five-year period ending May 31, 2025, is 11.85%, with an annualized current distribution rate of 1.58% as of the same date [4][5] - Cumulative total return from December 31, 2024, to May 31, 2025, reflects the percentage change in NAV, assuming reinvestment of distributions [6] - The Fund's investment strategy focuses on long-term capital growth, typically investing at least 65% of its assets in equity securities [7]

WESTFIELD, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Western New England Bancorp, Inc. (the “Company” or “WNEB”) (NasdaqGS: WNEB), the holding company for Westfield Bank (the “Bank”), announced that on May 30, 2025, the Company completed all repurchases under its existing stock repurchase plan (the “2024 Repurchase Plan”) at an average price per share of $8.79. The 2024 Repurchase Plan authorized the Company to repurchase a total of 1.0 million shares of the Company’s common stock, or approximately 4.6% of t ...

Core Viewpoint - CBL International Limited has announced a share repurchase program, reflecting confidence in its long-term potential and commitment to delivering value to shareholders [1][3]. Financial Performance - For FY2024, CBL reported consolidated revenue of $592.52 million, a 35.9% increase from $435.90 million in 2023, driven by a 38.1% increase in sales volume [3]. Strategic Focus - The company aims to expand its market presence, particularly in biofuels, and enhance its global supply network while driving operational efficiency and sustainable growth [4]. - CBL's strategic initiatives include the expansion of ports, diversification of its client base, and commitment to sustainable practices to position itself for growth as market conditions improve [5]. Company Overview - CBL International Limited, established in 2015, is a marine fuel logistics company based in the Asia Pacific region, providing vessel refueling solutions across over 60 major ports [6].

ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. A webcast of the above presentation may be accessed under "Events ...

ORION CORPORATION PRESS RELEASE 3 JUNE 2025 at 23.30 EEST U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy.This third approval is based on positive results from the pivotal Phase III ARANOTE trial and bro ...

VANCOUVER, BC and KIBBUTZ YIFAT, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- As a result of a review by the British Columbia Securities Commission (the “BCSC”), Beyond Oil Ltd. (CSE: BOIL; OTCQB: BEOLF; Frankfurt: UH9) (“Beyond Oil” or the “Company”) today issued the following press release providing clarifications related to certain German-language promotional media activities. As part of an awarness campaign focused on German speaking audiences, German-language materials referencing Beyond Oil were publishe ...

Core Insights - HeartCore Enterprises, Inc. has signed a Consulting Agreement with tmsuk Co. Ltd. for its 15th Go IPO consulting service win [1][2] - tmsuk will compensate HeartCore with $500,000 in fees and a warrant to acquire 3% of tmsuk's capital stock, subject to shareholder approval [2] - HeartCore's CEO expressed optimism about the demand for Go IPO services from Japanese growth companies despite market uncertainties [3] Company Overview - HeartCore is a leading enterprise software and data consulting services company headquartered in Tokyo, with additional offices in New York and San Francisco [4] - The company offers Software as a Service (SaaS) solutions and data analytics services to enhance customer experiences for enterprise clients [5] - HeartCore's Go IPOSM consulting services assist Japanese companies in going public in the U.S. [6]